---
title: "Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286952843.md"
description: "Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock News"
datetime: "2026-05-19T10:15:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286952843.md)
  - [en](https://longbridge.com/en/news/286952843.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286952843.md)
---

# Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock News

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock News

### Related Stocks

- [SVRA.US](https://longbridge.com/en/quote/SVRA.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [Savara reports 48-week open-label IMPALA-2 data for molgramostim in aPAP](https://longbridge.com/en/news/286952838.md)
- [Savara publishes corporate presentation focused on autoimmune PAP and MOLBREEVI program](https://longbridge.com/en/news/286955429.md)
- [12:06 ETGenScript Launches TurboCHO™ Protein Expression Kit, Delivering the Fastest Path to Antibodies in its Class](https://longbridge.com/en/news/286130384.md)
- [LifeSci Capital Keeps Their Buy Rating on Savara (SVRA)](https://longbridge.com/en/news/286648897.md)
- [Dyadic International Q1 net loss narrows](https://longbridge.com/en/news/286311192.md)